Aquestive Therapeutics’ Libervan Buccal Film Receives the US FDA’s Approval to Treat Seizure Activity
Shots:
- Aquestive’s Libervant buccal film (oral, 5mg, 7.5mg, 10mg, 12.5mg & 15mg) received the US FDA’s approval as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures), distinct from the usual pattern in epilepsy patients (2-5yrs.)
- The company further provided an update on Anaphylm (epinephrine) sublingual film, mentioning, its development is under progress for NDA submission, expected during the end of 2024
- The company is accepting & filling non-Medicaid prescriptions for libervant and will expand distribution in the upcoming wks. Libervant is a film formulation of diazepam that is administered buccally and developed as an acute treatment of frequent seizure episodes
Ref: Aquestive Therapeutics | Image: Aquestive Therapeutics
Related News:- Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
